Tag: BARDA
Vaxxas secures $2M grant from BARDA to develop needle-free mRNA vaccines
Vaxxas, a clinical-stage biotechnology company specializing in high-density microarray patch (HD-MAP) vaccine delivery, has been awarded a $2 million (AUD 3.2 million) grant as a Concept Stage winner in the United States Biomedical Advanced Research and Development Authority’s (BARDA) $50 million Patch Forward Prize.
SAB Biotherapeutics awarded $57.5 to manufacture its therapeutic candidate for COVID-19
Clinical stage biopharma company SAB Biotherapeutics has been awarded $57.5 million from BARDA and the US Department of Defence for the manufacturing of SAB-185,...
Featured Article
Circular beds: Revolutionising sustainable bedding in Australia
A new wave of innovation is transforming the Australian manufacturing sector, with sustainability at its core. ROBOVOID, in collaboration with Swinburne University, GT Recycling, and Sustainability Victoria, has developed a groundbreaking bed base made entirely from recycled plastic.
